Back to discover
Drug

Potassium Chloride

Approved · FDA
Emerging researchLate-stage development
Also known as Aminosyn 8.5 % with Electrolytes, Sulfite-Free, Aminosyn II 8.5 % with Electrolytes, Sulfite-Free, BSS Ophthalmic Solution, Cena K+68 more

Aminosyn 8.5 % with Electrolytes, Sulfite-Free, Aminosyn II 8.5 % with Electrolytes, Sulfite-Free, BSS Ophthalmic Solution, Cena K, Chlorid draselny, Colyte, Dextrose 5% and Plasma-Lyte 148, Ed K+10, GaviLyte-C, GaviLyte-G, GaviLyte-N, Gavilyte-H, GoLYTELY, Ionosol-MB, Isolyte P, Isolyte S, Isolyte S and 5% Dextrose, Isolyte S in 5 % Dextrose, K-10, K-8, K-Dur, K-Dur 20, K-Norm, K-Tab, KCl, Kaliumchlorid, Kaochlor, Kaochlor S-F, Kaon-CI, Kay Ciel, Klor-Con, Klorvess, Klotrix, Medi-Lyte, Micro-K, Micro-K LS, MoviPrep, Muriate of potash, Navstel, Normosol-R, Normosol-R PH 7.4, Normosol-R and 5% Dextrose, Normosol-R in 5 % Dextrose, NuLYTELY, NuLYTELY Cherry, NuLYTELY Lemon Lime, NuLYTELY Orange, Nutrilyte, PC-10, Physiolyte, Physiosol, Plasma-Lyte, Plasma-Lyte 148, Plasmalyte A, Pokonza, ProcalAmine 3, Slow-K, Sutab, Ten-K, Thermotabs, Tis-U-Sol, TriLyte, CHLORIDE (AS POTASSIUM), Chloride of potash, Dextrose and Potassium Chloride, Dextrose/Potassium Chloride/Sodium Chloride, K-Lyte/Cl, Monopotassium chloride, POTASSIUM (AS CHLORIDE), Potassium Chloride in Sodium Chloride, Potassium Chloride-Potassium Gluconate, Potassium Chloride-Sodium Chloride.

1
Research papers
2
Active clinical trials
6
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia

Clinical trial2026-07-10Results expected Q1 2029 · ClinicalTrials.gov

Matching Perfusion and Metabolic Activity in HFpEF

Clinical trial2026-06-02Results expected Q2 2027 · ClinicalTrials.gov

Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate

Clinical trial2023-10-25Results posted · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Potassium Chloride
Aliases & brands
Aminosyn 8.5 % with Electrolytes, Sulfite-FreeAminosyn II 8.5 % with Electrolytes, Sulfite-FreeBSS Ophthalmic SolutionCena KChlorid draselnyColyteDextrose 5% and Plasma-Lyte 148Ed K+10GaviLyte-CGaviLyte-GGaviLyte-NGavilyte-HGoLYTELYIonosol-MBIsolyte PIsolyte SIsolyte S and 5% DextroseIsolyte S in 5 % DextroseK-10K-8K-DurK-Dur 20K-NormK-TabKClKaliumchloridKaochlorKaochlor S-FKaon-CIKay CielKlor-ConKlorvessKlotrixMedi-LyteMicro-KMicro-K LSMoviPrepMuriate of potashNavstelNormosol-RNormosol-R PH 7.4Normosol-R and 5% DextroseNormosol-R in 5 % DextroseNuLYTELYNuLYTELY CherryNuLYTELY Lemon LimeNuLYTELY OrangeNutrilytePC-10PhysiolytePhysiosolPlasma-LytePlasma-Lyte 148Plasmalyte APokonzaProcalAmine 3Slow-KSutabTen-KThermotabsTis-U-SolTriLyteCHLORIDE (AS POTASSIUM)Chloride of potashDextrose and Potassium ChlorideDextrose/Potassium Chloride/Sodium ChlorideK-Lyte/ClMonopotassium chloridePOTASSIUM (AS CHLORIDE)Potassium Chloride in Sodium ChloridePotassium Chloride-Potassium GluconatePotassium Chloride-Sodium Chloride
RxNorm CUI
8591
ChEMBL ID
CHEMBL1200731
ATC codes
A12BA51A12BA01B05XA01
UNII
660YQ98I10
Regulatory jurisdictions
fda

Regulatory timeline

6 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2014-12-22
Latest approval
2026-06-12
Authorities
FDA
Total events
6
fdaU.S. Food and Drug Administration· 6 events
2026-06-12Supplemental approval
Supplemental approval: POTASSIUM CHLORIDE (NDA206814)
Evidence ↗
2020-03-05Label change
Label change: POTASSIUM CHLORIDE (NDA206814)
Evidence ↗
2019-05-01Supplemental approval
Supplemental approval: POTASSIUM CHLORIDE (NDA206814)
Evidence ↗

Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).

Clinical trials

22 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
22
registered trials across all phases
LATEST COMPLETION 2022
2
Active studies
2
Recruiting
9
Late-stage (III+)
12
Completed
8
Discontinued
PHASE DISTRIBUTIONn = 22
Phase 1 / 23Phase 210Phase 33Phase 43Phase N / A3

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes4
Dendrites1Eukaryotic Initiation Factor-4G1Open Reading Frames1Protein Biosynthesis1
Journals, researchers & institutions
Top journals
  • Nature neuroscience1
Leading researchers
  • Chen J1
  • Darnell RB1
  • Fak JJ1
  • Hacisuleyman E1
  • Hale CR1
  • Luo JD1
  • Noble N1
  • Saito M1
Leading institutions
free-text, unnormalised
  • Bay Area Institute of Science1
  • Bioinformatics Resource Center1
  • David H. Koch Institute for Integrative Cancer Research1
  • Department of Pharmacology and Cecil H. and Ida Green Center for Reproductive Biology Sciences1
  • Howard Hughes Medical Institute1
  • Laboratory of Molecular Neuro-oncology1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.